1. Home
  2. BLLN vs OUT Comparison

BLLN vs OUT Comparison

Compare BLLN & OUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BillionToOne Inc.

BLLN

BillionToOne Inc.

N/A

Current Price

$93.00

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Logo OUTFRONT Media Inc.

OUT

OUTFRONT Media Inc.

N/A

Current Price

$29.73

Market Cap

5.3B

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
BLLN
OUT
Founded
2016
2013
Country
United States
United States
Employees
713
N/A
Industry
Medical Specialities
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
5.3B
IPO Year
2025
2013

Fundamental Metrics

Financial Performance
Metric
BLLN
OUT
Price
$93.00
$29.73
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$126.71
$28.50
AVG Volume (30 Days)
797.8K
1.8M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
3.94%
EPS Growth
103.40
N/A
EPS
0.48
0.54
Revenue
$305,112,000.00
$1,831,700,000.00
Revenue This Year
$46.29
$6.19
Revenue Next Year
$30.14
$3.08
P/E Ratio
$198.23
$55.69
Revenue Growth
99.97
0.04
52 Week Low
$61.96
$16.97
52 Week High
$150.44
$34.96

Technical Indicators

Market Signals
Indicator
BLLN
OUT
Relative Strength Index (RSI) 39.93 41.71
Support Level $88.38 $30.14
Resistance Level $95.82 $33.57
Average True Range (ATR) 4.51 0.57
MACD 0.13 0.07
Stochastic Oscillator 47.48 46.56

Price Performance

Historical Comparison
BLLN
OUT

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

About OUT OUTFRONT Media Inc.

Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The company has two reportable operating segments: Billboard and Transit. It derives maximum revenue from Billboard Segment. The company geographically operates in United States and Canada, of which United States derive maximum revenue.

Share on Social Networks: